Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tacrolimus in combination, tacrolimus alone compared (TICTAC trial): a prospective randomized trial of minimized immunosuppression in adult heart transplant recipients

Next Previous
X
Search
Trial Profile

Tacrolimus in combination, tacrolimus alone compared (TICTAC trial): a prospective randomized trial of minimized immunosuppression in adult heart transplant recipients

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 08 Mar 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tacrolimus (Primary) ; Corticosteroids; Mycophenolate mofetil
  • Indications Heart transplant rejection
  • Focus Therapeutic Use
  • Acronyms TICTAC

    • Most Recent Events

    • 08 Feb 2023 Results(n=147) assessing Long term follow-up of the tacrolimus in combination, tacrolimus alone compared published in the Journal of Heart and Lung Transplantation
    • 27 May 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
    • 25 Apr 2013 Results of an analysis on the incidence of malignancy presented at the 33rd Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top